Increasing Incidence of Colon Cancer in the Young: Assessing the Tumor Biology

Valentine N Nfonsam, Hunter Jecius, Debbie Chen, Pamela N. Omesiete, Agnes N. Ewongwo, Emad - Elquza, Aaron J. Scott, Jana Jandova

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: The overall incidence of colon cancer (CC)is decreasing, but with increasing early-onset colon cancer (EOCC < 50 years old). Our recent study revealed unique overexpression of cartilage oligomeric matrix protein (COMP)in EOCC and its association with aggressiveness. The aim of this study was to assess CC biology, especially in the young, by evaluating the role of COMP in CC carcinogenesis and cancer progression, detecting COMP in serum and its association with disease stage. Study Design: Cancer and matching noninvolved tissue blocks from 12 sporadic EOCC and late-onset colon cancer (LOCC)patients of 4 disease stages were obtained from pathology archives. Ribonucleic acid expression profiling of 770 cancer-related genes using nCounter platform was performed. The COMP levels from 16 EOCC and LOCC serum samples were measured by ELISA. Carcinoembryonic antigen levels from these 16 samples were taken at the time of diagnosis. Transwell assay was performed to elucidate the role of COMP in motility and metastases. Results: Expression profiling revealed increased COMP levels in higher disease stage. There was 7-fold higher COMP expression (p ≤ 0.05)in stage III compare to stage I and its coexpression with GAS1, VEGFC, MAP3K8, SFRP1, and PRKACA. Higher COMP expression was seen in stage II compared with stage I (p = 0.07)and its coexpression withTLR2, IL8, RIN1, IRAK3, and CACNA2D2, and COMP was detectable in serum and showed significantly higher levels in EOCC compared with LOCC. Similar correlation was seen with CEA levels, but the difference was not significant. Transwell assay revealed significantly increased motility of HT-29 cells after treatment with recombinant COMP. Conclusions: These findings suggest different tumor biology between EOCC and LOCC. Cartilage oligomeric matrix protein plays a significant role in CC carcinogenesis and has potential as biomarker for CC, especially aggressive EOCC.

Original languageEnglish (US)
JournalJournal of the American College of Surgeons
DOIs
StatePublished - Jan 1 2019

Fingerprint

Cartilage Oligomeric Matrix Protein
Colonic Neoplasms
Incidence
Neoplasms
Carcinogenesis
Serum
HT29 Cells
Neoplasm Genes
Carcinoembryonic Antigen
Interleukin-8
Recombinant Proteins

ASJC Scopus subject areas

  • Surgery

Cite this

Increasing Incidence of Colon Cancer in the Young : Assessing the Tumor Biology. / Nfonsam, Valentine N; Jecius, Hunter; Chen, Debbie; Omesiete, Pamela N.; Ewongwo, Agnes N.; Elquza, Emad -; Scott, Aaron J.; Jandova, Jana.

In: Journal of the American College of Surgeons, 01.01.2019.

Research output: Contribution to journalArticle

@article{c669fc9009554abaaa6ba91ed3e72140,
title = "Increasing Incidence of Colon Cancer in the Young: Assessing the Tumor Biology",
abstract = "Background: The overall incidence of colon cancer (CC)is decreasing, but with increasing early-onset colon cancer (EOCC < 50 years old). Our recent study revealed unique overexpression of cartilage oligomeric matrix protein (COMP)in EOCC and its association with aggressiveness. The aim of this study was to assess CC biology, especially in the young, by evaluating the role of COMP in CC carcinogenesis and cancer progression, detecting COMP in serum and its association with disease stage. Study Design: Cancer and matching noninvolved tissue blocks from 12 sporadic EOCC and late-onset colon cancer (LOCC)patients of 4 disease stages were obtained from pathology archives. Ribonucleic acid expression profiling of 770 cancer-related genes using nCounter platform was performed. The COMP levels from 16 EOCC and LOCC serum samples were measured by ELISA. Carcinoembryonic antigen levels from these 16 samples were taken at the time of diagnosis. Transwell assay was performed to elucidate the role of COMP in motility and metastases. Results: Expression profiling revealed increased COMP levels in higher disease stage. There was 7-fold higher COMP expression (p ≤ 0.05)in stage III compare to stage I and its coexpression with GAS1, VEGFC, MAP3K8, SFRP1, and PRKACA. Higher COMP expression was seen in stage II compared with stage I (p = 0.07)and its coexpression withTLR2, IL8, RIN1, IRAK3, and CACNA2D2, and COMP was detectable in serum and showed significantly higher levels in EOCC compared with LOCC. Similar correlation was seen with CEA levels, but the difference was not significant. Transwell assay revealed significantly increased motility of HT-29 cells after treatment with recombinant COMP. Conclusions: These findings suggest different tumor biology between EOCC and LOCC. Cartilage oligomeric matrix protein plays a significant role in CC carcinogenesis and has potential as biomarker for CC, especially aggressive EOCC.",
author = "Nfonsam, {Valentine N} and Hunter Jecius and Debbie Chen and Omesiete, {Pamela N.} and Ewongwo, {Agnes N.} and Elquza, {Emad -} and Scott, {Aaron J.} and Jana Jandova",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.jamcollsurg.2019.03.022",
language = "English (US)",
journal = "Journal of the American College of Surgeons",
issn = "1072-7515",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Increasing Incidence of Colon Cancer in the Young

T2 - Assessing the Tumor Biology

AU - Nfonsam, Valentine N

AU - Jecius, Hunter

AU - Chen, Debbie

AU - Omesiete, Pamela N.

AU - Ewongwo, Agnes N.

AU - Elquza, Emad -

AU - Scott, Aaron J.

AU - Jandova, Jana

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: The overall incidence of colon cancer (CC)is decreasing, but with increasing early-onset colon cancer (EOCC < 50 years old). Our recent study revealed unique overexpression of cartilage oligomeric matrix protein (COMP)in EOCC and its association with aggressiveness. The aim of this study was to assess CC biology, especially in the young, by evaluating the role of COMP in CC carcinogenesis and cancer progression, detecting COMP in serum and its association with disease stage. Study Design: Cancer and matching noninvolved tissue blocks from 12 sporadic EOCC and late-onset colon cancer (LOCC)patients of 4 disease stages were obtained from pathology archives. Ribonucleic acid expression profiling of 770 cancer-related genes using nCounter platform was performed. The COMP levels from 16 EOCC and LOCC serum samples were measured by ELISA. Carcinoembryonic antigen levels from these 16 samples were taken at the time of diagnosis. Transwell assay was performed to elucidate the role of COMP in motility and metastases. Results: Expression profiling revealed increased COMP levels in higher disease stage. There was 7-fold higher COMP expression (p ≤ 0.05)in stage III compare to stage I and its coexpression with GAS1, VEGFC, MAP3K8, SFRP1, and PRKACA. Higher COMP expression was seen in stage II compared with stage I (p = 0.07)and its coexpression withTLR2, IL8, RIN1, IRAK3, and CACNA2D2, and COMP was detectable in serum and showed significantly higher levels in EOCC compared with LOCC. Similar correlation was seen with CEA levels, but the difference was not significant. Transwell assay revealed significantly increased motility of HT-29 cells after treatment with recombinant COMP. Conclusions: These findings suggest different tumor biology between EOCC and LOCC. Cartilage oligomeric matrix protein plays a significant role in CC carcinogenesis and has potential as biomarker for CC, especially aggressive EOCC.

AB - Background: The overall incidence of colon cancer (CC)is decreasing, but with increasing early-onset colon cancer (EOCC < 50 years old). Our recent study revealed unique overexpression of cartilage oligomeric matrix protein (COMP)in EOCC and its association with aggressiveness. The aim of this study was to assess CC biology, especially in the young, by evaluating the role of COMP in CC carcinogenesis and cancer progression, detecting COMP in serum and its association with disease stage. Study Design: Cancer and matching noninvolved tissue blocks from 12 sporadic EOCC and late-onset colon cancer (LOCC)patients of 4 disease stages were obtained from pathology archives. Ribonucleic acid expression profiling of 770 cancer-related genes using nCounter platform was performed. The COMP levels from 16 EOCC and LOCC serum samples were measured by ELISA. Carcinoembryonic antigen levels from these 16 samples were taken at the time of diagnosis. Transwell assay was performed to elucidate the role of COMP in motility and metastases. Results: Expression profiling revealed increased COMP levels in higher disease stage. There was 7-fold higher COMP expression (p ≤ 0.05)in stage III compare to stage I and its coexpression with GAS1, VEGFC, MAP3K8, SFRP1, and PRKACA. Higher COMP expression was seen in stage II compared with stage I (p = 0.07)and its coexpression withTLR2, IL8, RIN1, IRAK3, and CACNA2D2, and COMP was detectable in serum and showed significantly higher levels in EOCC compared with LOCC. Similar correlation was seen with CEA levels, but the difference was not significant. Transwell assay revealed significantly increased motility of HT-29 cells after treatment with recombinant COMP. Conclusions: These findings suggest different tumor biology between EOCC and LOCC. Cartilage oligomeric matrix protein plays a significant role in CC carcinogenesis and has potential as biomarker for CC, especially aggressive EOCC.

UR - http://www.scopus.com/inward/record.url?scp=85065416067&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065416067&partnerID=8YFLogxK

U2 - 10.1016/j.jamcollsurg.2019.03.022

DO - 10.1016/j.jamcollsurg.2019.03.022

M3 - Article

C2 - 30995524

AN - SCOPUS:85065416067

JO - Journal of the American College of Surgeons

JF - Journal of the American College of Surgeons

SN - 1072-7515

ER -